Coverage
Public drug plan coverage of GLP-1 medications
What the public drug plans of Ontario and British Columbia say about GLP-1 medications, and what is not confirmed for Quebec and Alberta.
Key facts
- Each province runs its own public drug plan with its own list of medications and conditions.
- Ontario lists Ozempic and Rybelsus as Limited Use benefits. Wegovy is not a benefit there.
- British Columbia covers semaglutide injection only with Special Authority.
- Quebec and Alberta: the current rules are not confirmed.
Ontario
The Ontario Drug Benefit formulary lists Ozempic as a Limited Use benefit with code 665, and the Rybelsus 3 mg tablet as a Limited Use benefit with code 662. A Limited Use benefit has criteria that the prescriber must confirm. The formulary page gives the criteria.
The formulary lists Wegovy only as Off-Formulary Interchangeable. It is not a benefit.
A search of the formulary on 2026-11-12 gave no product for Mounjaro, Zepbound or Saxenda.
British Columbia
BC PharmaCare lists semaglutide injection as a limited coverage drug that needs Special Authority. The coverage is for a maximum dose of 1 mg each week. The PharmaCare page says that the 2 mg dose is under review.
[Coverage of Rybelsus, Wegovy, Mounjaro, Zepbound and Saxenda in British Columbia: not confirmed.]
Quebec
RAMQ says that the public plan covers the drugs in its List of Medications, with the conditions that the list sets. In 2019 the Minister put Ozempic on the list as an exception drug.
[The current status of each GLP-1 medication on the RAMQ list: not confirmed.]
Alberta
The Alberta Drug Benefit List defines the drugs that the public plans of Alberta cover.
The rule for each GLP-1 medication in Alberta: not confirmed.
Private plans
A private plan has its own rules. Ask your insurer what it covers before you compare prices. The price lists on this site show the price before any coverage.